16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

• Full Name: Abhishek Jha

• Current Position & Affiliation: Co-founder and CEO, Elucidata

Country: **USA**

• Educational Background:

- University of Chicago PhD, Chemistry
- Indian Institute of Technology, Bombay Integrated Masters, Physical Chemistry

Professional Experience:

Abhishek led a 5-year career as a Senior Scientist at Agios Pharmaceuticals in Cambridge, MA where he led Agios's team to develop algorithms and tools to analyze metabolomic data to support multiple drug programs, developed an algorithm to integrate high-throughput metabolic data with transcriptional data and designed and deployed visualization tools for clinical data. His experience at Agios inspired him to start a business to build technology and solutions to enable data scientists like him, which became Elucidata when launched in 2015. As a founder of Elucidata, he is committed to building a biotech company for the future that will transform drug discovery by integrating different forms of biomedical data.

Professional Organizations:

- **Elucidata Corporation**
- Agios Pharmaceuticals

• Main Scientific Publications:

- 1. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
- Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization
- Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization
- Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition
- More https://scholar.google.com/citations?user=sVmnKhoAAAAJ&hl=en&oi=sr